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effectiveness results. The objective of this study was to determine
whether there was a relationship between the source of funding
and the reporting of positive results. METHODS: We conducted
a systematic review of the literature to identify economic evalu-
ations of bisphosphonates for the treatment of osteoporosis. We
extracted the source of funding, region of study, the journal name
and impact factor and all reported incremental cost effectiveness
ratios (ICERs). We identiﬁed which ICERs were under the thresh-
olds of $20,000, $50,000 and $100,000 A quality score between
0 and 7 was also given to each of the studies. We used generalized
estimating equations (GEE) for the analysis. RESULTS: The sys-
tematic review yielded 532 potential abstracts: Seventeen met our
ﬁnal eligibility criteria, 531 ICERs were analyzed, and ten studies
(59%) were funded by industry. There was no signiﬁcant differ-
ence between industry and non-industry funded studies reporting
ICERs below the thresholds of $20,000 and $50,000. However
industry sponsored studies were more likely to report ICERs
below $100,000 [OR = 4.69, 95%CI (1.77–12.43)]. Studies of
higher methodological quality (higher than 4.5) were less likely
to report ICERs below $20,000 and $50,000 than studies of
lower methodological quality (score under 4). Methodological
quality was not signiﬁcantly different between studies reporting
ICERs under $100,000. CONCLUSIONS: Our study shows that
funding source (industry vs. non-industry) did not signiﬁcantly
affect the reporting of ICERs below $20,000 and $50,000 thresh-
olds. Methodological quality might be a more signiﬁcant factor
than source of funding in differentiating which studies are likely
to report favorable ICERs, with the higher quality studies sig-
niﬁcantly less likely to report ICERs below $20,000/QALY and
$50,000/QALY.
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OBJECTIVE: To determine the annual drug and administration
costs and dosage patterns for patients with rheumatoid arthritis
(RA) treated with inﬂiximab or abatacept from a managed
care perspective. METHODS: A retrospective analysis of medical
claims was performed using the PharMetrics claims database.
Patients with RA were identiﬁed from Janaury 1, 2003-
December 31, 2005 for those prescribed inﬂiximab and February
1, 2006-December 31, 2006 for those prescribed abatacept as
ﬁrst or subsequent biologic treatment. Patients were followed
until medication switch, discontinuation, or end of study period.
Primary outcomes of interest were annual drug and administra-
tion costs and dose escalation (increase in dose, dosing frequency
or both). Patients’ weight information required to calculate dose
were unavailable, therefore paid amounts were used as proxy for
dose. RESULTS: From ﬁrst to last infusion, patients receiving
inﬂiximab (n = 1913) as ﬁrst or subsequent biologic experienced
an average dose increase of 17% and 39%, respectively. A
total of 58% and 73% patients prescribed inﬂiximab as ﬁrst
or second-plus biologic experienced dose escalation, respectively.
For patients receiving abatacept (n = 184) as ﬁrst or subsequent
biologic, dose increase averaged 1.2% and 6.5%, respectively
(no increase in number of vials for either). The dosing interval for
patients receiving abatacept followed the recommended dosing
regimen. Patients treated with inﬂiximab experienced an increase
in dosing frequency, averaging 49 days earlier in treatment (from
4th to 14th infusion) and 33 days later in treatment (15th to last
infusion). The estimated annual drug plus infusion administra-
tion cost of ﬁrst and subsequent biologic therapy was $13,354
and $14,465 for abatacept and $16,608 and $23,913 for inﬂix-
imab, respectively. CONCLUSION: Patients treated with inﬂix-
imab experienced an increase in dosage and/or dosing frequency,
resulting in an increase in real world treatment costs. Patients
treated with abatacept showed no considerable increase in dose
or dosing frequency from ﬁrst to last infusion.
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OBJECTIVE: To evaluate the cost-effectiveness of etoricoxib
(90 mg), celecoxib (200/400 mg), and the non-selective NSAIDs
naproxen (1000 mg) and diclofenac (150 mg) in the initial treat-
ment of ankylosing spondylitis (AS) in the UK. METHODS: A
Bayesian cost-effectiveness model was developed to estimate the
costs and beneﬁts associated with initiating AS treatment with
etoricoxib, celecoxib, diclofenac, or naproxen. Efﬁcacy, safety
and medical resource and cost data were obtained from the
literature. With mixed treatment comparison meta-analysis the
obtained efﬁcacy estimates were synthesized. Treatment beneﬁt
and degree of disease activity, as reﬂected with BASFI and
BASDAI scores, were related to quality adjusted life years
(QALYs) and disability related costs. Other cost outcomes
related to drug acquisition, gastrointestinal and cardiovascular
safety were taken into consideration. Uncertainty in the source
data was translated into uncertainty in cost-effectiveness esti-
mates and therefore decision uncertainty. RESULTS: There was
more than 98% a probability that etoricoxib results in greater
QALYs than the other interventions. Over a 30-year time
horizon, etoricoxib is associated with about 0.5 more QALYs
than the other interventions. At 2 years there is a 77% probabil-
ity that etoricoxib shows the lowest cost. This increases to >99%
at 30 years. At 30 years etoricoxib is expected to save 19,460
relative to celecoxib (200/400 mg) and 14,140 relative to
naproxen and diclofenac. For a willingness-to-pay ceiling ratio of
20,000 per QALY there is a >97% probability that etoricoxib
is the most-cost-effective treatment. Additional analysis with
different assumptions, including celecoxib 200 mg, and ignoring
cost-offsets associated with AS disability, supported these ﬁnd-
ings. CONCLUSION: This economic evaluation demonstrated
that etoricoxib is the most cost-effective NSAID treatment for AS
patients in the UK.
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OBJECTIVE: Chronic pain conditions, such as osteoarthritis
(OA) and mechanical chronic low back pain (CLBP), among
active workers cost employers ~$61.2 billion/yr in lost produc-
tive time, which includes both reduced performance while at
work and days of work missed (absenteeism). An analysis of lost
productivity time from a 56-week, open-label study was con-
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